Herbert Samuel Jennings
Growth, tech, biotech, solar

Partnership Could Mean High Alpha For ChemoCentryx

Partnership Could Mean High Alpha for ChemoCentryx

ChemoCentryx (Nasdaq:CCXI) is a biopharmaceutical smallcap whose pipeline & process [1] are oriented on the development of chemokine pathway drugs. [2] On January 15, 2014 at the 32nd Annual JP Morgan Healthcare Conference, ChemoCentryx CEO Thomas Schall announced his intention to pursue strategic partnerships with other companies in the resumption and advancement of Vercirnon through clinical phase 3 trials. [3] The announcement begs for new insight on ChemoCentryx... specifically about how much a partnership could be worth to the company and its shareholders. In order to answer, I will derive an estimate for the cost of the phase 3, and build a range estimate of "hypothetical ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details